Anti-Cancer treatment targets activated platelets in tumor microenvironment

A novel chemotherapeutic agent transport system is based on the binding of an antibody-drug conjugate specifically directed to an exterior protein on energizing platelets in the tumor microenvironment. Based on the premise that platelets in the blood are progressively conceding as mediators of tumor swelling and metastasis, investigators at the Baker Heart and Diabetes Institute (Melbourne, Australia) hypothesized that activated platelets in the tumor microenvironment could provide a targeting epitope for tumor-directed Chemotherapy.
The scFv single-chain antibody was equating chemically to the highly potent microtubule inhibitor, monomethyl auristatin E. Monomethyl auristatin E (MMAE) is an antimitotic agent which inhibits cell division by blocking the polymerization of tubulin. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to an antibody, which directs it to the cancer cells. The investigators showed that scFvGPIIb/IIIa-MMAE could be conjugated with the fluorescent dye Cyanine7 for in vivo imaging and potential diagnostic use.https://www.biotechdaily.com/genomics-proteomics/articles/294776946/anti-cancer-treatment-targets-activated-platelets-in-tumor-microenvironment.html